Notice ID: f36eb9975e5b4f928396d9d01a0415e5Special Notice
HT9426-27-NOI-049825
Active, responses due . Full description on SAM.gov.
Overview
- Response deadline
- 1:00 PM EST
- Posted
- November 18, 2026
- Notice type
- Special Notice
- NAICS
- 541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Agency
- Department of WarDEFENSE HEALTH AGENCY (DHA)
Notice details
- Office
- DEFENSE HEALTH AGENCY
- Place of performance
- Mitochon Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA 19422-1574., Blue Bell, Pennsylvania, 19422
- Last updated
- Nov 18, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- HT9426-27-NOI-049825
- Notice ID
- f36eb9975e5b4f928396d9d01a0415e5
Description
The Defense Health Agency Contracting Activity (DHACA) on behalf of the WRAIR, CMPN, ISB, intends to negotiate on a sole source basis in accordance with RFO 6.103 with vendor Mitochon Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA 19422-1574. The contractor shall supply two (2) Batches of the proprietary prodrug MP201 to ISB for testing Acute Stress Reactions (ASRs). This includes providing quality control documentation and dosage background information. Additionally, the contractor shall provide informational support to the ISB research team by assisting with preparing reports and manuscripts related to MP201. Each batch of synthesized MP201 shall consist of a freshly made lot of prodrug to determine target dosage in the range of approximately 8 - 80 mg/kg body weight. These doses shall be developed in quantities to support oral administration in mice. THIS NOI IS NOT A REQUEST FOR COMPETITIVE PROPOSALS, and no solicitation document exists for this requirement. Meaningful submissions received in response to this notice will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government.. Responsible, interested parties may identify their interest by submitting capability statements (using PDF, MS Word, or Excel attachments), in writing, by 2:00 p.m. Eastern Time, 31 December 2026 to Herbert Keen at herbert.e.keen.civ@health.mil and Mr. Lance Nowell at lance.l.nowell.civ@health.mil. Supporting evidence must be furnished in sufficient detail to demonstrate the firms ability to provide the stated capability. Information and materials submitted in response to this request WILL NOT be returned. DO NOT SUBMIT CLASSIFIED MATERIAL. Responses will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the Government. If no responses are received, the DHACA will proceed with the sole source contract issued to Mitochon Pharmaceuticals, Inc.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Documents
Files (1)
- Download
Notice of Intent to Sole Source - M201 ProDrug_Approved for posting 16NOV26.pdf
126 KBAdded in Special Notice version 1Posted
Lifecycle
- 1Version 1Special Notice
Notice of Intent (NOI) to Sole Source proprietary prodrug MP201 to ISB for testing Acute Stress Reactions (ASRs)
- 2Version 2Special NoticeCurrent
HT9426-27-NOI-049825
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
HT9426-27-NOI-049825
Archive Date
Jan 18, 2027
Office Address
FORT DETRICK, MD, 21702